Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8041 - 8048 of 12089 results
Department of State Releases August 2016 Visa Bulletin
July 12, 2016| Alert| Viewpoint
FDA Comes Through on Promise to Release NGS Device Draft Guidelines Expeditiously
July 12, 2016| Alert| Viewpoint
Eighth Circuit Issues Decision Significant for All Executives of FDA-Regulated Businesses
July 12, 2016| Blog| Viewpoint
EU Adopts Cybersecurity Directive: What US Companies Need to Know
July 11, 2016| Blog| Viewpoint
Privacy Shield Passes Art. 31 Hurdle; European Parliament LIBE Committee Advisory Vote Later Today
July 11, 2016| Blog| Viewpoint
Senate Passes Bill Requiring Labeling for Genetically Engineered Foods
July 11, 2016| Blog| Viewpoint
USPTO Fast-Tracks Cancer Immunotherapy Patent Applications
July 8, 2016| Blog| Viewpoint
Biodiagnostic Laboratory Services Sentenced; Another Physician Pleads Guilty
July 8, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|